TraMetinib - CAS# 871700-17-3 0201 and safe mGlu5 inhibitor with

and safe mGlu5 inhibitor with good oral bioavailability and long half-life supportive of once-daily administration

InChiKey: DZHFTEDSQFPDPP-HWYNEVGZSA-L

35(20):2574-83

Azacitidina

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

TraMetinib - CAS# 871700-17-3 0201 and safe mGlu5 inhibitor withTrametinib, also known as GSK1120212, CAS No. 871700 17 3, is a n orally bioavailable inhibitor of mitogen activated protein kinase kinase (MEK MAPK ERK kinase) with potential antineoplastic activity. Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity threonine tyrosine kinases often upregulated in